Trials / Completed
CompletedNCT03426033
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin
Phase 1, Drug-Drug Interaction Study To Evaluate The Effect Of Multiple Doses Of ISIS 681257 40 mg Subcutaneous Injections On The Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Akcea Therapeutics · Industry
- Sex
- All
- Age
- 16 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This is a single center, open label, single sequence, two-treatment, two-period drug-drug interaction study to evaluate the effect of multiple doses of ISIS 681257 on the pharmacokinetics of a single dose of warfarin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ISIS 681257 | Xmg dose administered as a subcutaneous injection |
| DRUG | Warfarin | 25mg tablet administered orally |
Timeline
- Start date
- 2017-12-15
- Primary completion
- 2018-02-25
- Completion
- 2018-02-25
- First posted
- 2018-02-08
- Last updated
- 2018-04-05
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT03426033. Inclusion in this directory is not an endorsement.